Baynes Roy D. 4

What Happened

• Roy D. Baynes, a director of Nurix Therapeutics (NRIX), was granted an award covering 31,250 shares on 2026-05-15. The filing reports this as a derivative acquisition (grant/award) at $0.00 (no cash paid at grant). This is a stock option-style award and does not represent an immediate purchase of common shares.

Key Details

• Transaction date: 2026-05-15; transaction type: Grant/Award (code A).
• Amount: 31,250 shares; reported price: $0.00 (derivative grant).
• Vesting: 100% vests on the earlier of (a) the date of the next annual meeting or (b) May 15, 2027, subject to continued service (per footnote).
• Shares owned after transaction: not disclosed in the provided filing.
• Filing timeliness: reported on 2026-05-15 (not indicated as late).

Context

• This was an option/award grant (derivative), not an exercise or market purchase—no immediate change in share ownership until vesting/exercise. Director awards are commonly part of compensation; they do not by themselves indicate a buy or sell market signal. If and when the award vests and is exercised or shares are sold, separate Form 4 transactions would disclose those actions.